The group is mailing pharmacogenetic information back to patients, with plans to deliver genetic disease risk and carrier screening results.
The personalized medicine company hopes to use the new array to inform new consumer and clinical tests, while also making it available to others for research.
The EU will fund the effort through 2026, but the Cypriot government will contribute an additional €15 million over the next 15 years.
The project will provide approved researchers with access to samples and deidentified data collected from volunteer patients with Duchenne muscular dystrophy.
By participating in the project, the company, located in Tokyo, hopes to improve its cloud-based data management services while winning over new customers.
The ongoing effort — called Your DNA, Your Say — based its results on responses from nearly 9,000 people from the US, UK, Canada, and Australia.
As part of the shift, DNA.Land, which was run as an academic research project, will delete all data by the end of the month and ask customers to resubmit it.
The firm plans to address the fact that only 2 percent of human DNA samples used in pharmaceutical research are from Africans or those of African ancestry.
The acquisition will result in a new DLS division called HudsonAlpha Discovery that will provide a range of services to the pharma, biotech, and diagnostics industries.
The project dovetails with a separate effort to sequence the whole exomes of the samples, the first 50,000 of which became available to researchers this month.
The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.
ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.
CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.
In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.